155.39USD-0.92%Mkt Cap: 9.13B $P/E: —1d ago
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It off…
Industry Peers
Medical DevicesIndicators:|
Key Statistics
Company
Market Cap9.13B $
Enterprise Value8.95B $
Revenue (TTM)551.35M $
Gross Profit282.76M $
Net Income (TTM)-187.69M $
Revenue/Share9.583 USD
Last Price155.39 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINUS3773221029
Valuation
P/E (Trailing)—
P/E (Forward)365.11
PEG—
EV/EBITDA-202.30
EV/Revenue16.24
P/S16.55
P/B13.52
EPS (TTM)-3.29
EPS (Forward)0.43
52W Range
73.1693% of range161.53
52W High161.53 USD
52W Low73.16 USD
Profitability
Gross Margin55.72%
Oper. Margin-13.19%
EBITDA Margin-8.02%
Profit Margin-36.99%
ROE-28.60%
ROA-21.01%
Growth
Revenue Growth41.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.79M $
CapEx (TTM)24.27M $
FCF Margin1.10%
FCF Yield0.07%
Net Debt-170.82M $
Net Debt/EBITDA3.86
Balance Sheet
Debt/Equity0.16
Current Ratio5.43
Quick Ratio4.43
Book Value/Sh11.50 USD
Cash/Share4.713 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)162.92 USD
Upside (mean)+4.8%
Target Range138.00 USD – 190.00 USD
$138.00+4.8% to mean$190.00
# Analysts12
Ownership
Shares Out.58.73M
Float56.56M
Insiders3.62%
Institutions102.22%
Short Interest
Short Ratio4.0d
Short % Float9.18%
Short % Out.7.58%
Shares Short4.45M
Short (prev mo.)3.12M
Technical
SMA 50133.98 (+16.0%)
SMA 200113.25 (+37.2%)
Beta0.75
S&P 52W Chg19.63%
Avg Vol (30d)718.50K
Avg Vol (10d)747.22K
Technical Indicators
RSI (14)68.2
MACD7.2427
MACD Signal6.5933
MACD Hist.+0.6493
BB Upper163.08 USD
BB Middle144.70 USD
BB Lower126.33 USD
BB Width25.40%
ATR (14)6.349 USD
Vol Ratio (20d)0.91x